Westwood Holdings Group Inc. raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 11.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 528,618 shares of the company’s stock after purchasing an additional 53,925 shares during the period. Westwood Holdings Group Inc. owned 1.39% of Omnicell worth $25,638,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Omnicell by 4.0% in the 4th quarter. BlackRock Inc. now owns 4,839,191 shares of the company’s stock worth $234,701,000 after purchasing an additional 187,069 shares during the last quarter. Conestoga Capital Advisors LLC grew its position in shares of Omnicell by 10.8% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,792,313 shares of the company’s stock valued at $86,927,000 after buying an additional 174,607 shares during the last quarter. Eagle Asset Management Inc. grew its position in shares of Omnicell by 36.8% during the 4th quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock valued at $66,047,000 after buying an additional 367,687 shares during the last quarter. Carillon Tower Advisers Inc. bought a new stake in shares of Omnicell during the 4th quarter valued at about $38,612,000. Finally, Fisher Asset Management LLC grew its position in shares of Omnicell by 0.3% during the 4th quarter. Fisher Asset Management LLC now owns 530,569 shares of the company’s stock valued at $25,733,000 after buying an additional 1,650 shares during the last quarter.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Piper Jaffray Companies boosted their price objective on shares of Omnicell from $38.00 to $44.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Craig Hallum lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reissued a “buy” rating and set a $63.00 target price on shares of Omnicell in a research note on Thursday, February 1st. Finally, Oppenheimer reissued a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Omnicell has an average rating of “Hold” and a consensus target price of $56.14.
In other news, Chairman Randall A. Lipps sold 8,186 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total value of $361,903.06. Following the completion of the sale, the chairman now directly owns 224,206 shares of the company’s stock, valued at approximately $9,912,147.26. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gary S. Petersmeyer sold 575 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $44.43, for a total transaction of $25,547.25. The disclosure for this sale can be found here. Corporate insiders own 3.77% of the company’s stock.
Omnicell stock traded down $0.80 during trading on Monday, reaching $43.50. 14,944 shares of the company’s stock were exchanged, compared to its average volume of 303,513. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.73 and a quick ratio of 1.28. The firm has a market cap of $1,718.10, a price-to-earnings ratio of 86.86, a price-to-earnings-growth ratio of 3.65 and a beta of 0.75. Omnicell, Inc. has a 52-week low of $38.00 and a 52-week high of $55.40.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.02. The firm had revenue of $198.26 million during the quarter, compared to analyst estimates of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. Omnicell’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.37 EPS. research analysts anticipate that Omnicell, Inc. will post 0.77 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/19/omnicell-inc-omcl-shares-bought-by-westwood-holdings-group-inc.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.